apollomics presents vebreltinib data in patients with non-small cell lung cancer with metex14 skipping mutations at european society for medical oncology (esmo) congress 2024
FOSTER CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical...